Two batches of the prescription contraception Tydemy have been recalled over fears that their reduced potency could end in unexpected pregnancy.
The Food and Drug Administration issued its warning to consumers on Tuesday, following a July 29 voluntary recall by the drugmaker.
Lupin Pharmaceuticals reported that testing showed the pills had decreased levels of the inactive ingredient ascorbic acid and high levels of a “known impurity.”
The FDA noted it has not received any reports of antagonistic events related to Tydemy.
The lots (L200183 and L201560) within the recall were distributed between June 3, 2022, and May 31, 2023, and have expiration dates of January or September 2024.
The FDA said patients should proceed taking Tydemy, but immediately contact their pharmacist, physician, or medical provider for advice.
Consumers, wholesalers, distributors, and retailers with recall questions should contact Inmar Rx Solutions at (866) 480-8206.
Recalled lots ought to be returned to Inmar Rx Solutions for reimbursement.
The Post has reached out to Lupin Pharmaceuticals for comment.
